2026-11-06 09:00 EST — Friday open under STRESS: VST/MRNA BMO prints, semis bounce while SM suspended, CEG peer into Mon

Hourly research report. Research slot: Friday November 6, 2026, 9:00 AM EST (America/New_York). Market/API evidence captured approximately 8:58–9:15 AM EST; issuer primaries opened during finalization. Later publication does not refresh those price observations. Screening/research, not investment advice. No rule is implemented by this report.

Actionable for today's trading: YES. VST's actual BMO print (Ongoing Ops Adj EBITDA raise/narrow + 2027 initiation) after the S-141 multi-day crush changes open gap-risk for VST and ρ≈0.85 peer CEG; short_momentum stays suspended — a semis indicated bounce is not an SM reactivation; MRNA's beat/raise is healthcare context for SM residuals REGN/PFE/LLY/GILD/VRTX (not automatic peer inheritance); watch the 10:00 AM ET VST webcast.

1. Incremental focus (not a repeat of Nov 5 close/postclose)

The Nov 5 17:00 postclose and 16:00 close wrap covered NET/TEAM/MCHP and leftover AMC energy names. This hour is Friday open under stress with new actual BMO releases and a fresh premarket run:

1. VST + MRNA BMO prints already released (issuer primaries below). VST webcast still ahead at 10:00 AM ET; MRNA call was 8:00 AM ET.
2. Semis indicated rebound after Thu SMH −11.21%, while the SM residual list (including nine semis) remains suspended.
3. MR fade-long watchlist into the open: HON, TMO, BLK, AMGN, ZS, COIN, BAC, MSTR (ZS indicatedGapPct +3.49%).
4. CEG peer risk into Mon 2026-11-09 BMO (S-132 / S-004 / S-141 handoff).

2. Live TRAI evidence and clock audit

Read-only API checks returned HTTP 200 around finalization. Linked endpoints are mutable, not immutable historical snapshots. Sources: latest, events, correlations, regime, macro, scorecard.

Scorecard constraint [TRAI above]: liveRules all — n 196, mean R −0.0524, distinctDays 10, perDayMeanR −0.0502, day-bootstrap 90% CI [−0.1259, +0.0203], enoughDays false; exitMix TARGET 0 / TIME 191 / STOP 5. Do not claim new live-rule edge. Live-rule uses 10:00 AM EST entry, 1 ATR stop / 2 ATR target, 60-minute time stop.

3. Vistra VST: beat-and-raise print after S-141 crush [V-P]

Primary [V-P], issuer release November 6, 2026: Vistra Reports Third Quarter 2026 Results. Webcast 10:00 AM ET Nov 6.

• GAAP Q3 net income $1,140M (includes unrealized hedge gain $559M expected to settle in future years).
• Ongoing Operations Adjusted EBITDA $2,378M (>50% YoY vs $1,581M).
• Operating revenues $6,347M vs $4,971M YoY.
• Raised midpoint / narrowed 2026 Ongoing Ops Adj EBITDA to $7.1–$7.5B and FCFbG $4.3–$4.7B; initiated 2027 Ongoing Ops Adj EBITDA $7.7–$8.5B and FCFbG $4.3–$5.1B.
• Board authorized additional $1.5B buybacks (~$2.5B authorization remaining; expect by YE 2028).
• Cogentrix ~5,500 MW closed Oct 2026; Pulaski 405 MW solar (Microsoft PPA); Deer Creek 100 MW; 20y 207 MW PPA with New Era at Odessa.
• Hedged ~100% 2026 / 98% 2027 / 78% 2028 expected generation volumes as of Oct 30, 2026.
• Prior 2026 guide midpoint on this IR page excerpt: UNKNOWN — not restated as a single prior midpoint in the opened release; do not invent one. Guidance language is "raised the midpoint and narrowed the range."

Path into print (prior KB / Nov 5 research): 11-04 C 120.29 (−13.83%, residZ −6.84, SM suspended) → 11-05 last ~112.95 (−6.10%) → ~−19% two-day into BMO — live S-141 case. TRAI last-4 avg \|gap\| only 1.49%.

TRAI indicated (8:58 AM ET run): VST indicatedGapPct +5.86% still carrying a short_momentum residual tag under suspended status. Do not reactivate SM.

Secondary [S-1], Nov 6: Investing.com headlines cite ~5–5.7% pre-open surge and revenue-vs-consensus disagreement across outlets (example). Prefer issuer tables; treat consensus and early % as secondary. Exact live quote here: UNKNOWN beyond TRAI indicatedGapPct and those dated secondary claims.

4. Moderna MRNA: revenue beat, FY growth raise, cash guide lift [V-P]

Primary [V-P], issuer via Newswire November 6, 2026: Moderna Reports Third Quarter 2026 Financial Results. Call 8:00 AM ET Nov 6.

• Total revenue Q3 $1,313M (+29% YoY vs $1,016M); US $780M / intl $533M; net product sales $1,273M.
• Net income $162M; diluted EPS $0.38 (vs loss $0.51 YoY).
• Raises 2026 revenue growth outlook to 15%–25% from previous "up to 10%".
• Improves 2026 GAAP opex outlook by ~$0.2B; R&D ~$2.7B (was ~$2.9B); YE cash/investments $8.1–$8.3B (was $4.7–$5.2B) — convert notes ~$2.6B net proceeds contribute (issuer states this explicitly).
• mFLUSIVA FDA approval (5th product); intismeran Phase 3 positive with Merck (HR 0.58 recurrence/death). Norovirus Phase 3 interim did not meet early-success criteria; no additional cohort this season (issuer).

Secondary [S-1], Nov 6: Investing.com / CNBC claim premarket surge and consensus beats — surge figures disagree across outlets (~10% / ~8.5% Investing.com articles vs CNBC "~3%" premarket). Consensus EPS/revenue are vendor estimates [S-1]. Prefer issuer numbers. TRAI 8:58 AM indicatedGapPct for MRNA was −1.85% — not synchronized with later secondary surge headlines; do not invent a reconciled live %. Treat price reaction as UNKNOWN at a single synchronized clock beyond those dated secondary claims and the TRAI snapshot.

Peer read-through hypothesis (not established): MRNA is in correlation cluster 20 (asOf Nov 5), not the large-cap pharma SM residual basket. Issuer revenue growth is attributed primarily to international COVID vaccine sales — weak documented automatic transmission into REGN/LLY/GILD/VRTX; PFE has the clearest franchise overlap among SM residuals. Use as healthcare context, not a fade/chase signal for those residuals.

5. Semis bounce while short_momentum SUSPENDED

TRAI [above]: after Thu SMH −11.21%, SM residual indicated gaps include TSM +7.28%, KLAC +8.81%, AMAT +9.1%, ADI +2.93%, TXN +2.23%, MCHP +1.02%. Bucket status remains suspended (36 rows).

Secondary market context [S-1], Nov 6: Investing.com (published/updated Nov 6) cites SMH premarket rebound (~+5% by ~08:51 ET in that piece) after Thursday's AI selloff; midterms/data-center policy narrative; jobs report 8:30 ET. CNBC Nov 6 similarly frames Thu AI/data-center selloff and Friday recovery signs. Exact open levels: UNKNOWN here.

Policy implication for today: bounce ≠ SM reactivation. S-141 and standing SM suspension policy still apply. Large indicated gaps also feed S-006 caution — do not auto-fade huge opens same-day without data.

6. MR fade-longs, CEG peer risk, calendar handoffs

• MR fade-longs (latest): HON, TMO, BLK, AMGN, ZS, COIN, BAC, MSTR. ZS indicatedGapPct +3.49% into the open after Thu stress MR context from the 17:00 report — still not validated edge (scorecard enoughDays false).
• CEG: events asOf Nov 6 — Mon 2026-11-09 BMO, gapRisk imminent, last-4 avg \|gap\| 3.60%. Correlations cluster 23 with VST, avgRho 0.845. TRAI indicatedGapPct +3.02% on the 8:58 AM run (no current bucket signal). S-132 / S-004 peer flag into Monday remains live; VST's guidance raise does not by itself neutralize peer gap-risk sizing for CEG (needs data — see S-143 proposal).
• Other calendar (events): BRK-B AMC 11-07; TTD/KKR/HIMS/OXY/CEG/MARA 11-09. Not independently re-researched this hour beyond the calendar.

7. Proposed tests only — extend existing items; optional S-143

No live engine changes. Deduplicate into S-141, S-132/S-004, S-006, SM suspension policy.

1. S-141 evidence add: VST actually printed a guidance raise/narrow + 2027 initiation after the ~−19% two-day crush while SM suspended. Record reaction-morning indicated/open path separately from the pre-print crush. Still no SM reactivation (naive short into a raise morning is the suspension's point).
2. S-132 / S-004: CEG ρ 0.845 peer into Mon 11-09 BMO after VST's positive revision morning — tag expected peer gap-risk; measure whether reporter guide-raise changes peer |gap| distribution vs baseline.
3. S-006: if MRNA/VST open huge, do not fade same-day without data; n=4 history is fragile.
4. Optional new PROPOSAL S-143 (NEEDS DATA): after a multi-day crush into own BMO, if the issuer raises forward EBITDA/FCFbG (or equivalent) guidance, treat reaction-morning peer gap-risk as asymmetric — still size for \|gap\| overrun on ρ≥0.7 peers, but do not auto-fade the reporter itself. Distinct from S-141 (which is about crush→resize and SM non-reactivation) and from S-077 (MR fade-short on own beat-and-raise). Keep as PROPOSAL / NEEDS DATA only.

Acceptance: timestamped sources, no look-ahead, costs, day-level resampling, OOS, multiple-testing caution; live scorecard <30 distinct days remains insufficient.

8. Whiggity consultation and remaining unknowns

• Whiggity [whiggity]: consult file /workspace/trai-research/whiggity-2026-11-06-0900.md has a real reply (Monica chat; tool budget exhausted after MRNA-focused opens). Verified-only points used above: MRNA figures match issuer/secondary reproduction; prior Q2 guide "up to 10%" confirms the raise base [V-P Q2]; cash guide includes ~$2.6B convertible proceeds (dilution inside cash guide); norovirus miss is a negative pipeline item alongside the beat; MRNA revenue attributed primarily to international COVID sales → weak documented read-through to REGN/LLY/GILD (PFE clearer overlap) — treated as hypothesis/context, not a finding that peers must move. Whiggity left VST issuer PR, BLS jobs figures, and public SMH premarket quotes [UNV] in that consult — those are filled here from issuer IR / TRAI / dated secondary articles instead, not invented from whiggity.
• Exact synchronized live quotes for MRNA/VST/CEG/SMH at 9:00 AM ET: UNKNOWN beyond TRAI indicatedGapPct snapshot and disagreeing secondary headlines.
• Prior VST 2026 Ongoing Ops Adj EBITDA midpoint before today's raise: UNKNOWN from the opened IR page.
• Jobs (Employment Situation) 8:30 ET headline figures: not independently opened here (secondary Investing.com notes stronger-than-expected payrolls; [S-1]).
• VST 10:00 AM call content: not yet available at report freeze.
• Live-rule edge: still not established.

9. Actionable checklist for today (research framing only)